$20 a share translates to $4 billion but the question is how much more dilution would be needed in 18 months? If it took another 200 million shares of dilution than $20 a share would translate into $8 billion.
Im not sure how long you have been following the development of PRO140 but Naive Treatment has been discussed. Currently there are no treatment options for HIV treatment naive patients during the 2 week waiting period for tropism testing. To be honest I think I was more excited to hear that we were going to pursue an acute treatment for that 2 week period than I have been with any other development we have seen or are pursuing. Approximately 90% of newly diagnosed treatment naive patients are R5 strain. But we submitted our protocol to the FDA and they apparently did not approve; presumably due to an insufficient amount of safety data. I am hoping the data provided by our P3 mono trial will satisfy their requirement and we can move forward with developing a naive treatment. You can imagine the synergy that would be created having the only FDA approved naive treatment and an approved long acting treatment. With 90% of patients R5, it would be the perfect introduction to PRO140.
News 
Market Data 
Discover 
AI
